Strategic Alternatives cover image

How to Build and Sell a Biotech in 2024

Strategic Alternatives

00:00

Investor Priorities in Biotech Acquisitions

Exploring the focus of investors on de-risked assets with high upside potential in biotech companies, emphasizing aspects like market timeline, revenue generation, and asset value. The episode wraps up by inviting listeners to connect with RBC Capital Markets for more insights and discussions.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app